Adoptive Cell Therapies (ACT) & CAR T Cell
With over 80 unique hematological malignancy cell lines, such as the CD19+ Raji-Luc lymphoma model, the MV-411-Luc leukemia model, and the MM.1S-Luc multiple myeloma model, we lead the industry with market-relevant models for your studies. We also have an ever-expanding list of solid tumor models validated in NSG mice to support the field’s drive toward approval of an adoptive cell therapy (ACT) in a solid tumor indication.